Non-alcoholic fatty liver disease, now formally renamed metabolic dysfunction-associated steatotic liver disease (MASLD) by international consensus, affects an estimated one in four adults worldwide and represents a leading cause of chronic liver disease. Its progression from simple fat accumulation to inflammation, fibrosis, and cirrhosis is shaped by many factors beyond diet and exercise alone, including the composition of the gut microbiome and how intestinal bacteria communicate with the liver through the gut-liver axis.
Akkermansia muciniphila, a gram-negative bacterium residing in the intestinal mucus layer that typically constitutes more than 1 percent of a healthy gut microbiome, has become one of the most studied microbes in metabolic disease research. A growing body of preclinical work and an emerging systematic review suggest that reduced Akkermansia abundance is associated with fatty liver pathology and that restoring this bacterium may influence liver fat accumulation, bile acid handling, and gut barrier integrity. This article reviews what the research actually shows, including where evidence remains preliminary, and what it means for anyone interested in the gut-liver connection.
Key Takeaways
- The gut-liver axis is a recognized driver of NAFLD/MASLD progression, with gut barrier disruption and altered bile acid metabolism as key mechanisms; Akkermansia muciniphila is proposed to influence both [1][2].
- A 2025 systematic review found consistent signals in animal models that Akkermansia supplementation reduces liver steatosis and modulates bile acid metabolism, but robust human randomized controlled trials in NAFLD are limited [3].
- Bile acid metabolism appears to be a central mechanistic bridge between Akkermansia activity and liver outcomes, though at least one animal study found that Akkermansia expansion via cholic acid improved diabetes while exacerbating steatohepatitis, highlighting context-dependency [4].
- In mice on a high-fat, high-sugar diet, pectin supplementation reduced hepatic lipid accumulation and enhanced both A. muciniphila and E. coli; whether this works in people with fatty liver has not been tested [5][12].
- Akkermansia supplements are not FDA-approved to treat any liver condition; the human evidence base is still early-stage, and anyone with liver disease should consult a physician before using probiotic supplements.
The Gut-Liver Axis: Why the Microbiome Matters in NAFLD/MASLD
The gut and liver are anatomically and functionally intertwined. The portal vein delivers blood from the intestines directly to the liver, meaning the liver is constantly exposed to bacterial metabolites, lipopolysaccharides (LPS), and other microbial products that cross the intestinal wall. When gut barrier integrity is compromised, this exposure increases significantly, triggering inflammatory signaling cascades that are directly implicated in fatty liver progression [1].
A 2026 FASEB review examining the gut-liver axis in MASLD described how disrupted microbial communities, reduced gut barrier function, altered bile acid profiles, and inflammatory signaling all converge to drive hepatic lipid accumulation and disease progression [2]. This framework helps explain why two people eating similar diets can have very different liver health outcomes depending on the composition of their gut microbiome.
Research published in EBioMedicine (2025) used microbiome and metabolomics profiling in fatty liver disease and linked gut microbial composition to lipid metabolism in the liver and to the liver’s regenerative capacity; profiling shows association and does not by itself show that the microbiome causes these outcomes [6].
Akkermansia muciniphila: Proposed Roles in Fatty Liver Pathology
A 2025 systematic review published in BMC Gastroenterology examined the available evidence for Akkermansia muciniphila’s therapeutic potential in non-alcoholic fatty liver disease [3]. The review included thirteen studies, mostly in C57BL/6 mice on high-fat diets, and found that in mice A. muciniphila reduced body weight, hepatic steatosis and serum lipids and improved insulin sensitivity; the absence of clinical trials limits translatability to people [3].
Research note: In obese mice, A. muciniphila treatment improved fatty liver and reduced the abundance of the gut fungus Fusarium [20].
Several mechanisms have been proposed. In mouse and cell work, Akkermansia is proposed to reinforce the intestinal barrier and so reduce endotoxin translocation to the portal circulation; this has not been shown in people with fatty liver [13][3][14][15]. Akkermansia’s outer-membrane protein Amuc_1100 has also been proposed to independently signal through gut receptors to support tight-junction integrity and metabolic regulation, though most of this evidence comes from cell and animal studies.
A mouse study published in Microbial Biotechnology (2023) found that Akkermansia supplementation in high-fat diet-fed mice alleviated metabolic-associated fatty liver disease by reshaping the gut microbial community and altering bile acid profiles, two mechanisms with direct relevance to hepatic lipid handling [7].
Bile Acid Metabolism: A Central Mechanistic Bridge
Bile acids are synthesized in the liver from cholesterol, secreted into the gut, and then modified by gut bacteria before being reabsorbed. This enterohepatic circulation is a two-way communication channel between the liver and the microbiome, and its disruption has been implicated in NAFLD progression. Gut bacteria influence whether primary bile acids are converted to secondary bile acids, which have distinct signaling properties affecting hepatic fat metabolism and glucose homeostasis.
A 2024 paper published in Cell reported, in mice and cell work, that a bile acid made by Bacteroides uniformis alleviated metabolic-associated steatohepatitis (MASH) by promoting growth of A. muciniphila; this is a route to raising Akkermansia, not an Akkermansia supplement [8]. A separate 2023 NPJ Biofilms and Microbiomes study demonstrated that gut microbiome composition determines the therapeutic efficacy of obeticholic acid, a bile acid receptor agonist used in NAFLD treatment, by modulating bile acid metabolism pathways [9]. These findings reinforce that the relationship between gut bacteria and bile acid chemistry is central to liver fat outcomes.
A 2025 study in Genes to Cells examined a dietary intervention that induced Akkermansia expansion via cholic acid supplementation in TSOD mice, finding it upregulated FGF-15 (a bile acid-responsive hormone) and improved diabetic parameters. However, the same intervention also exacerbated steatohepatitis in that model [4]. This is an important finding: it underscores that bile acid-Akkermansia interactions are context-dependent and that results in one metabolic model do not automatically generalize to all conditions.
Preclinical Evidence: What Animal Models Reveal
Much of the mechanistic work on Akkermansia and fatty liver has been conducted in rodent models. A 2021 Microbiome study examining genetically obese ob/ob and diabetic db/db mice found that Akkermansia abundance was substantially reduced compared to lean controls, and that this reduction coincided with compromised gut barrier integrity and elevated systemic inflammation [10]. These are correlations in mice, and they do not show that Akkermansia depletion drives liver disease [3].
The 2023 Microbial Biotechnology study using high-fat diet-fed mice supplemented with Akkermansia muciniphila reported reductions in hepatic lipid accumulation and improvements in metabolic markers, mediated in part through bile acid pathway modulation and microbiome recomposition [7]. A 2025 International Journal of Biological Sciences study found that citrus pectin supplementation, which enriched Akkermansia among other microbes, was associated with reduced liver fat accumulation through an indole lactic acid and bile acid synthesis pathway [5], suggesting that dietary approaches supporting Akkermansia growth may engage some of the same downstream mechanisms.
Animal models, particularly high-fat diet rodent studies and genetic obesity models, do not always translate directly to human disease. Results from these studies are best interpreted as mechanistic hypothesis-generation rather than definitive clinical evidence.
Systematic Review Summary: Where the Human Evidence Stands
The 2025 systematic review in BMC Gastroenterology [3] included thirteen studies, mostly in C57BL/6 mice on high-fat diets, so its evidence is preclinical [3]. The reviewers found consistent signals across animal studies supporting reduced liver steatosis, improved gut barrier function, and modulation of bile acid and lipid metabolism with Akkermansia supplementation. Human evidence is sparse: a 2026 review states that human studies of pasteurized A. muciniphila report heterogeneous metabolic and weight-related outcomes, not liver histology or validated MASLD efficacy endpoints, and next-generation probiotics have only entered MASLD-specific trials with no efficacy result reported [13][2]. The review noted that robust, randomized controlled trials in NAFLD patients are limited, making it premature to draw firm clinical conclusions about therapeutic dosing or efficacy in humans.
In people, the available link is an association. In 94 adults with NAFLD and elevated liver enzymes, Akkermansia composition was reduced compared with healthy people, but the supplementation work in that paper used Lactobacillus in mice, not Akkermansia [19].
A 2025 study in the Journal of Ethnopharmacology examining a traditional herbal formula for NAFLD found improvements in liver markers associated with changes in gut microbiota composition and gut-adipose tissue crosstalk, with Akkermansia among the modulated microbes [11]. This is weak evidence for Akkermansia specifically: a herbal formula changes many things at once, so it cannot show that Akkermansia drove the liver changes.
The overall picture is one of promising preclinical evidence and plausible mechanistic pathways, set against an early-stage human evidence base. Commercially available Akkermansia supplements have begun to enter the market, but they are not FDA-approved to treat, cure, or prevent NAFLD, MASLD, or any liver condition.
Practical Takeaway: Diet, Lifestyle, and Supporting the Gut-Liver Axis
Akkermansia muciniphila thrives on the mucin layer and on fermentable dietary fibers. Foods and fibers linked to higher Akkermansia abundance, mostly in animal or small studies, include legumes, cranberry extract and pectin. A systematic review found few diet trials measured Akkermansia, and inulin did not raise it in a pilot in adults with type 1 diabetes [16][17][5][12][18]. The citrus pectin study noted above [5] illustrates how a dietary substrate enriching Akkermansia can produce downstream bile acid changes relevant to liver fat, though isolating Akkermansia as the sole variable in dietary studies is rarely possible.
For individuals concerned about fatty liver disease, the current evidence base suggests that gut microbiome health is one piece of a multifactorial picture that also includes dietary quality, physical activity, body weight management, and medical management of underlying conditions such as type 2 diabetes and dyslipidemia. No supplement, including Akkermansia-based products, should be viewed as a replacement for these foundational lifestyle interventions or for physician-supervised medical care.
🛒 Where to Buy Akkermansia muciniphila
- Pendulum Akkermansia
delayed-release capsules, 100M AFU: Live A. muciniphila strain (WB-STR-0001); single-strain with chicory inulin, third-party tested. - Codeage Akkermansia Muciniphila
capsules, 100M AFU, 90 ct: Lower-cost Akkermansia plus chicory inulin synbiotic; 3-month supply, gluten-free. - Double Wood Akkermansia Probiotic + Postbiotic
capsules, per label: Budget Akkermansia option marketed around GLP-1 and postbiotic support.
As an Amazon Associate we earn from qualifying purchases. Akkermansia is a live, oxygen-sensitive strain: choose a delayed-release, third-party-tested product with a stated live AFU count.
A Note on the Evidence
The majority of evidence linking Akkermansia muciniphila to fatty liver improvement comes from animal models; robust human clinical trials in NAFLD/MASLD patients are limited, and no Akkermansia supplement is FDA-approved to treat, cure, or prevent any liver condition. Individuals with existing liver disease, immunocompromised status, active inflammatory bowel disease, or those on immunosuppressive therapy should consult a qualified physician before using any probiotic supplement. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
What is the gut-liver axis and why does it matter in fatty liver disease?
The gut-liver axis refers to the bidirectional signaling pathway between the intestinal microbiome and the liver, mediated by the portal vein, bile acids, and microbial metabolites. When gut barrier integrity is disrupted, bacterial endotoxins reach the liver and activate inflammatory pathways that contribute to fat accumulation and disease progression [1]. A 2026 FASEB review described how microbial imbalance, altered bile acids, and inflammatory signaling converge specifically in MASLD [2].
Is Akkermansia muciniphila lower in people with NAFLD?
In one study of 94 adults with NAFLD and elevated liver enzymes, Akkermansia composition was reduced compared with healthy people, an association only. Mouse studies, including genetically obese ob/ob and db/db mice compared with lean controls [10], also report reduced abundance, but the 2025 systematic review covered mouse models [3], and establishing causality in humans requires more rigorous longitudinal and interventional research [19][3].
How might Akkermansia muciniphila help reduce liver fat accumulation?
Proposed mechanisms include reinforcing the gut mucus layer to reduce LPS translocation to the liver, modulating bile acid profiles to improve hepatic lipid signaling, and recomposing the broader gut microbial community in ways that reduce fat deposition. A mouse study found that Akkermansia supplementation alleviated high-fat-diet-induced fatty liver through these bile acid and microbiome remodeling pathways [7].
What did the 2025 systematic review on Akkermansia and NAFLD conclude?
The systematic review published in BMC Gastroenterology (2025) found consistent preclinical evidence that Akkermansia muciniphila supplementation reduced liver steatosis, improved gut barrier function, and modulated bile acid metabolism in animal models of NAFLD [3]. The reviewers emphasized that robust human randomized controlled trials in NAFLD patients remain limited, making clinical translation premature at this stage.
Can diet support Akkermansia and benefit the liver?
In mice, certain dietary fibers have been linked to higher Akkermansia and less liver fat. A 2025 study in mice on a high-fat, high-sugar diet found that pectin supplementation reduced hepatic lipid accumulation and enhanced both A. muciniphila and E. coli [5][12]. High-fiber and polyphenol-rich dietary patterns are generally associated with supporting Akkermansia abundance, though dietary studies rarely isolate Akkermansia as the sole explanatory variable.
Are there any risks with Akkermansia supplements for people with liver disease?
Live probiotic formulations, including Akkermansia-based products, carry potential risks for immunocompromised individuals, those on immunosuppressive therapy, and people with active inflammatory bowel disease. Additionally, one animal study found that a cholic acid-induced Akkermansia expansion improved diabetes markers but exacerbated steatohepatitis in a specific mouse model [4], suggesting that bile acid-Akkermansia interactions are context-dependent and outcomes are not uniformly beneficial across all metabolic conditions. Anyone with liver disease should consult a physician before using Akkermansia supplements.
References
- Miura K et al. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World journal of gastroenterology (2014). PMID 24966608
- Zhu S et al. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID 41824007
- Asghari P et al. Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review. BMC gastroenterology (2025). PMID 41257640
- Kato M et al. Cholic Acid-Induced Akkermansia Expansion and FGF-15 Upregulation Improve Diabetes While Exacerbating Steatohepatitis in TSOD Mice. Genes to cells : devoted to molecular & cellular mechanisms (2025). PMID 41251061
- Pan Z et al. Citrus Pectin Supplementation Alleviated Hepatic Lipid Accumulation through Gut Microbiota Indole Lactic Acid Promoting Hepatic Bile Acid Synthesis and Excretion. International journal of biological sciences (2025). PMID 40860180
- Hu Y et al. Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver disease. EBioMedicine (2025). PMID 39644773
- Wu W et al. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microbial biotechnology (2023). PMID 37377410
- Nie Q et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway. Cell (2024). PMID 38653239
- Liu J et al. Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism. NPJ biofilms and microbiomes (2023). PMID 37258543
- Suriano F et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome (2021). PMID 34183063
- Shi J et al. Zexie-Baizhu Decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk. Journal of ethnopharmacology (2025). PMID 39182702
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- Wei G et al. Polystyrene microplastics exposure increases the disruption of intestinal barrier integrity and gut microbiota homeostasis during obesity and aging. Journal of environmental sciences (China) (2026). PMID 41765542
- Gao Y et al. Aging-Dependent Hepatic YAP1 Reduction Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease via Gut Microbiota Dysbiosis With Akkermansia muciniphila Downregulation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID 41854525
- Hossain MA et al. Legume intake on gut microbiome and glycemia in type 2 diabetes management: narrative review. Frontiers in nutrition (2026). PMID 41994099
- Fernando F. Anhê et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut (2014). PMID 25080446
- Ojetti V et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences (2026). PMID 41636295
- Lee NY et al. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clinical and molecular hepatology (2021). PMID 33317254
- Liu C et al. Akkermansia muciniphila ameliorates fatty liver through microbiota-derived α-ketoisovaleric acid metabolism and hepatic PI3K/Akt signaling. iScience (2025). PMID 40343268
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
